Fresenius Medical Care Signals Strong 2025, Tough 2026
Fresenius Medical Care ((FMS)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fresenius Medical Care’s latest earnings call painted a picture of robust 2025 execution, marked by strong margin expansion, cash generation and a successful Value-Based Care turnaround. Management was upbeat on the structural improvements and long-term potential but candid about 2026 being a transition year, with regulatory headwinds and one-off benefits normalizing the unusually strong 2025 base.
Profitability Surges on Margin Expansion
Fresenius Medical Care delivered a standout 2025, with operating income up 27% and a group margin of 11.3%, signaling a sharp improvement in profitability. The fourth quarter was even stronger, as margin jumped to 13.9%, a 430 basis‑point increase year on year, with all three segments contributing.
Fourth-Quarter Revenue and EPS Accelerate
The fourth quarter showcased exceptional operating momentum, with organic revenue up 8% and 7% at constant currency, underlining healthy underlying demand. Adjusted operating income climbed about 53% at constant currency while EPS surged roughly 68%, supported in part by ongoing share buybacks.
Strong Cash Generation and Shareholder Returns
Operating cash flow reached EUR 2.7 billion in 2025, underscoring the business’s strong cash‑generating capacity and funding flexibility. The company returned capital aggressively, repurchasing about EUR 585 million of shares under the first tranche of its EUR 1 billion program and proposing a 3% higher dividend of EUR 1.49.
FME25+ Transformation Delivers Ahead of Plan
The FME25+ transformation program remained a key profit driver, with accumulated sustainable savings reaching EUR 804 million by year‑end. In 2025 alone, incremental savings of EUR 238 million exceeded the EUR 220 million target, and management now expects another EUR 250 million in 2026 on the way to EUR 1.2 billion total by 2027.
Value-Based Care Swings to Profit
The company’s Value-Based Care business staged a striking turnaround, with Q4 organic revenue up 42% and operating income positive at EUR 29 million. For the full year 2025, the segment essentially broke even with EUR 3 million in operating income, a sharp improvement from a EUR 28 million loss in 2024.
Care Delivery Growth and 5008X Rollout
Care Delivery posted 7% organic revenue growth for 2025, including 8% in the U.S., while Q4 margin improved to 16.4%, up 440 basis points. The firm soft‑launched its 5008X CAREsystem in the U.S. and began a large‑scale 2026 rollout, targeting replacement of about 20% of its installed base and training around 7,200 staff to transition roughly 36,000 patients.
Balance Sheet Strengthens as Leverage Falls
The balance sheet continued to improve, with net leverage reduced from 3.4x at the end of 2022 to 2.5x by the end of 2025, now at the low end of the target band. Net debt and lease liabilities fell about 6% versus the prior period, giving the group more strategic flexibility for investment and shareholder returns.
Regulatory and Volume Headwinds Weigh on 2026
Looking to 2026, management expects revenue and operating income to be broadly flat versus the elevated 2025 base, reflecting intensifying external pressures. Regulatory changes, including the phasing out of certain reimbursement benefits and Affordable Care Act subsidy effects, are expected to hit earnings by EUR 150–200 million in 2026.
One-Off Benefits Inflate 2025 Comparisons
Investors were reminded that 2025 profits were flattered by temporary reimbursement and product benefits that will not repeat. Phosphate binders contributed around EUR 220 million and catheter‑related TDAPA solutions around EUR 90 million in 2025, meaning these items will be neutral or fade in 2026 and make year‑over‑year comparisons tougher.
China Pressure Hits Care Enablement
Care Enablement remained a weak spot, with Q4 revenue down 3% and earnings off about 6%, largely due to regulatory tightening in China. Volume‑based procurement, stricter tenders and delays are estimated to have shaved around EUR 50 million off EBIT in 2025, and while the drag should ease, some impact is expected to linger into 2026.
Muted U.S. Treatment Volumes
U.S. same‑market treatment growth was broadly flat in the fourth quarter, held back by elevated mortality earlier in the year and a spike in missed treatments in December. Management now assumes flat U.S. same‑market growth again in 2026, versus its longer‑term ambition to return to growth above 2% as patient mortality normalizes.
Special Items, FX and Portfolio Actions
Reported results were also shaped by special items and external factors, which investors need to strip out to gauge underlying performance. In Q4 alone, operating income was hit by EUR 111 million of special charges tied to FME25+ costs, portfolio optimization and a remeasurement of an investment, while FX and divestitures also damped reported growth.
Transitional Costs for Strategic Investments
The company flagged elevated transitional spending in 2026 tied to key growth projects that will temporarily weigh on profits but are expected to pay off later. These include EUR 100–150 million for the 5008X rollout and IT upgrades, plus about EUR 350 million of one‑time FME25+ costs across 2026–27, layered on top of ongoing transformation benefits.
Guidance and Medium-Term Outlook
For 2026, Fresenius Medical Care guided to broadly flat group revenue and operating income, with a margin between 10.5% and 12% and a stronger first half before TDAPA benefits roll off. Management reiterated medium‑term targets of 3–7% annual operating income growth through 2028, significant cumulative FME25+ savings by 2027 and ambitions for mid‑teens group margins and modest Value‑Based Care profitability by 2030.
The earnings call portrayed a company that has regained its footing, delivering strong 2025 results and clear proof that its transformation and Value-Based Care strategies are working. While 2026 will be a tougher, more complex transition year due to regulatory normalization, one‑offs and investment costs, management’s tone and targets suggest confidence in a steadily improving earnings and margin profile beyond the near term.
